Psychopharmacology of anxiety disorders
نویسندگان
چکیده
Exposure of the general population to a 1:4 lifetime risk of disabling anxiety has inspired generations of fundamental and clinical psychopharmacologists, from the era of the earliest benzodiazepines (BZ) to that of the selective serotonin reuptake inhibitors (SSRIs) and related compounds, eg, the serotonin and norepinephrine reuptake inhibitors (SNRIs). This comprehensive practical review summarizes current therapeutic research across the spectrum of individual disorders: generalized anxiety disorder (GAD), panic disorder (PD) and agoraphobia (social anxiety disorder), compulsive disorder (OCD), phobic disorder (including social phobia), and posttraumatic stress disorder (PTSD). Specific diagnosis is a precondition to successful therapy: despite substantial overlap, each disorder responds preferentially to specific pharmacotherapy. Comorbidity with depression is common; hence the success of the SSRIs, which were originally designed to treat depression. Assessment (multidomain measures versus individual end points) remains problematic, as-frequently-do efficacy and tolerability The ideal anxiolytic remains the Holy Grail of worldwide psychopharmacologic research.
منابع مشابه
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.
These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented toge...
متن کاملCurrent issues in child and adolescent psychopharmacology. Part 2: Anxiety and obsessive–compulsive disorders, autism, Tourette’s and schizophrenia
Part 1 of this two-part consideration of child and adolescent psychopharmacology focused on attention–deficit hyperactivity disorder (ADHD), depression and bipolar disorder (Coghill, 2003). This second paper concentrates on current pharmacological approaches to the treatment of anxiety disorders, obsessive–compulsive disorders, autism, Tourette syndrome and schizophrenia. The aim is to describe...
متن کاملPsilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future.
متن کامل
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.
This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A c...
متن کاملListening to the past: history, psychiatry, and anxiety.
This article explores the history of psychiatry and the rise of biological psychiatry and suggests ways in which the study of history can shed light on current psychiatric practice and debate. Focusing on anxiolytics (meprobomate in the 1950s and benzodiazepines in the 1960s, 1970s, and 1980s) as a case study in the development of psychopharmacology, it shows how social and political factors co...
متن کامل